Press review

 - 

Antibiotic use in livestock could result in drug resistance - report

Country : UK

Keywords :
WARSAW, Dec 8 (APM) - Antibiotic use in livestock could have a major impact on the development of such bacteria, according to a study on drug resistant bacteria recently published by The Lancet Infectious Diseases and reported in Rzeczpospolita (pA15) on Tuesday.
The molecular analysis of historic salmonella samples conducted by researchers from the Pasteur Institute in Paris suggests that the ampicillin resistance gene developed in humans several years before the antibiotic was launched onto the market, meaning that the gene could have developed as a result of the common practice of adding penicillin to livestock fodder in the 50s and the 60s.
According to estimates, drug resistant bacteria kill 25,000 Europeans each year and this number could grow to 10 million people globally by 2050.

Britain's NHS could substantially reduce number of reimbursable drugs

Britain's National Health Service could remove 3,000 drugs from the reimbursement list to save 190 million pounds (217.3 million euros) a year, reported Puls Biznesu (p24) on Monday.
Simon Stevens, chief executive of the NHS, said the institution should not be paying for less effective therapies and drugs prescribed by doctors that are widely available in supermarkets at a fraction of the price that the NHS has to pay for them.
The NHS estimates that a packet of paracetamol costs 50p (0.6 euro) in supermarkets, while the NHS pays 34 pounds (39 euros). The UK currently spends 9 billion pounds (10.3 billion euros) on reimbursement per year, of which 650 million pounds (743.4 million euros) is spent on non-prescription drugs.
Removing some of the reimbursable drugs used in 36 conditions, including colds, bug bites, dandruff or warts, could bring savings of 190 million pounds (217.3 million euros) a year. The payer is also considering cutting reimbursement on homeopathic and herbal products, some analgesics, vitamins and omega-3 fish oil supplements.

Mabion preparing for share issue

Polish biotech Mabion, which is working on MabThera biosimilar, MabionCD20, is preparing for a share issue on a foreign stock exchange, from which it expects to raise 440 million zlotys (104.5 million euros), reported Parkiet Gazeta Gieldy (p1 & p7) on Thursday.
Artur Chabowski, Mabion’s CEO, said the share issue could take place in the first quarter of 2018. He added that the delay in filing MabionCD20 in the EU arose from the need to prepare additional analyses and that the complete set of documentation should be filed by April next year.

Biomed-Lublin to focus on boosting sales of current products

Biomed-Lublin appears to be getting back on track after its failed investment in a blood plasma fractionation plant in Mielec and intends to grow with its current portfolio, reported Puls Biznesu (p8-9) on Monday and Parkiet Gazeta Gieldy (p6) on Friday.
Biomed recently sold the rights to its Lakcid probiotics product line to Polpharma for 17 million zlotys (4 million euros) and will continue to produce and sell these products to the new owner at the negotiated prices over the coming five years. Biomed decided to make this step, because Lakcid was the only over-the-counter product in its portfolio and the company did not have sufficient resources to provide full sales and marketing support for the brand, reported Puls Biznesu.
Biomed intends to focus on sales of its tuberculosis vaccine, Onko-BCG vaccine, used in non-invasive bladder cancer, and Distreptaza suppositories, reported both newspapers.
The company claims its current production capacity utilisation is 100%, which is why it will be doubled for Distreptaza and tripled for Onko-BCG by November 2018, as Biomed already has customers for quantities which are higher than its present output. Biomed also intends to establish a new production plant in Lublin within three years, reported Parkiet.
Biomed expects to reduce its debt to 44 million zlotys (10.5 million euros) by the end of the year and recently reported its first profitable quarter after a long period of losses, with a net profit of 53,000 zlotys (12,600 euros) generated in the third quarter of the year, reported Parkiet.
rw/nh

[NH8P0MZG4]

TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT

Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to our last stories

Request a trial to assess coverage that includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.